Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$8.35
+1.2%
$7.70
$6.50
$9.48
$2.61B1.061.46 million shs503,870 shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$6.90
+4.3%
$6.66
$6.08
$16.76
$701.92M-1.271.14 million shs712,850 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$53.14
+5.7%
$46.79
$35.11
$54.23
$2.63B0.97461,287 shs221,386 shs
Organon & Co. stock logo
OGN
Organon & Co.
$9.99
+0.4%
$9.49
$8.01
$23.10
$2.60B0.63.55 million shs1.36 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-1.90%+0.49%+8.27%+11.04%+20.97%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-0.30%0.00%-8.07%-9.08%-55.34%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-0.40%+3.89%+8.39%+21.22%+39.99%
Organon & Co. stock logo
OGN
Organon & Co.
+2.26%-0.60%+4.18%-20.92%-50.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
3.1334 of 5 stars
3.53.00.00.03.20.81.3
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
1.7109 of 5 stars
3.62.00.00.00.02.50.0
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.8706 of 5 stars
3.60.00.04.22.02.50.6
Organon & Co. stock logo
OGN
Organon & Co.
4.891 of 5 stars
3.34.01.73.71.73.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
3.00
Buy$11.6039.01% Upside
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3.14
Buy$29.00320.59% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.13
Buy$65.5023.26% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0080.27% Upside

Current Analyst Ratings Breakdown

Latest DAWN, OGN, AMRX, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
5/22/2025
Organon & Co. stock logo
OGN
Organon & Co.
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$73.00
5/15/2025
Organon & Co. stock logo
OGN
Organon & Co.
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.00
5/13/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy
5/13/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.00
5/9/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.00
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$25.00
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $27.00
5/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Inline
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$2.83B0.92$1.38 per share6.05($0.35) per share-23.84
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$131.16M5.33N/AN/A$4.99 per share1.38
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$336.89M7.81N/AN/A$4.70 per share11.31
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.41$5.07 per share1.97$1.83 per share5.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-$116.89M-$0.04N/A13.91N/A-0.46%-188.26%5.34%N/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/29/2025 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.883.472.670.9911.92%227.43%7.34%8/5/2025 (Estimated)

Latest DAWN, OGN, AMRX, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.31N/AN/AN/A$107.91 millionN/A
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.93N/AN/AN/A$1.55 billionN/A
7/29/2025Q2 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.35N/AN/AN/A$35.55 millionN/A
5/14/2025Q1 2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million
5/6/2025Q1 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million
5/2/2025Q1 2025
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.14$0.19+$0.05$0.04$714.78 million$695.42 million
5/1/2025Q1 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.80%N/A2.78%N/A

Latest DAWN, OGN, AMRX, and MIRM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.8%5/12/20255/12/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/A
1.40
0.84
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/A
10.62
10.55
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.32
3.22
3.04
Organon & Co. stock logo
OGN
Organon & Co.
16.49
1.67
1.15

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
87.95%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,100313.42 million258.73 millionOptionable
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
60101.36 million95.08 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14049.53 million38.21 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.96 million256.32 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$8.35 +0.10 (+1.15%)
As of 02:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Day One Biopharmaceuticals stock logo

Day One Biopharmaceuticals NASDAQ:DAWN

$6.90 +0.29 (+4.31%)
As of 02:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$53.14 +2.87 (+5.71%)
As of 02:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$9.98 +0.04 (+0.35%)
As of 02:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.